CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
Low/High/Placebo Dose Keppra (Levetiracetam)drug
Likely dose
Low/High/Placebo Dose Keppra (Levetiracetam) 2.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01554683
NCT01554683N/ACompleted
CompareCT.gov

Seizure-like Hippocampal Activity in Alzheimer's Disease Neurodegeneration

Beth Israel Deaconess Medical Center·interventional·Posted Mar 15, 2012·Updated Jul 23, 2020

In Brief

A clinical study evaluating Low/High/Placebo Dose Keppra (Levetiracetam) for Alzheimer's Disease and Seizures. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The main purpose of this research project is to study how seizure-like activity affects the blood flow in the brain of patients with Alzheimer's disease (AD). Changes in blood flow can change memory and thinking ability, as happens in Alzheimer's disease. The investigators are using a study drug called Levetiracetam, which helps control seizure-like activity to see if it can help change the abnormal blood flow in the brain that is seen in some people with Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Seizures
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 15, 2012
Enrollment StartFeb 1, 2012
Primary CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 14.3 years ago

Interventions

Low/High/Placebo Dose Keppra (Levetiracetam)drug

Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)